John de Groot, MD
Division Chief of Neuro-Oncology
Specialties: Adult brain tumors, including glioma, glioblastoma, and meningioma
Dr. de Groot is the Division Chief of the Neuro-Oncology Division at UCSF and an internationally recognized leader in the field of brain tumors and molecular targeted therapies. He specializes in the treatment of adults with brain tumors, including glioblastomas and other gliomas.
Dr. de Groot's research expertise is in glioma angiogenesis and therapeutic approaches to address tumor resistance to anti-angiogenic agents. He has been involved in numerous clinical trials evaluating novel treatments for patients with glioblastoma. Dr. de Groot has also mentored countless junior faculty, clinical fellows, postdoctoral research fellows, residents, medical students and undergraduate students – inspiring the next generation of innovative clinical and basic science research.
1992: BA, Human Biology, Stanford
1998: MD, The University of Texas Medical Branch at Galveston
1998-1999: Clinical Internship, Internal Medicine, Johns Hopkins University School of Medicine
1999-2002: Clinical Residency, Neurology, Johns Hopkins University School of Medicine
2002-2004: Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center
2003-2004: Clinical Specialist, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
2004-2010: Assistant Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
2006-2010: Adjunct Assistant Professor, Graduate School of Biomedical Sciences at Houston
2010-2016: Associate Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
2016-Present: Professor, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center
2003: Basic Research Fellowship Award, American Brain Tumor Association
2003: Scholarship Award, American Association for Cancer Research (AACR)
2008-2010: Career Development Award, The ASCO Cancer Foundation
2020: Nominee, Emil Friedrich Award for Excellence in Translational Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
My clinical work is a constant reminder of the privilege and responsibility entrusted in me to care for this truly unique patient population.